protein C (PC), protein S (PS), while a number of acquired conditions is known to be related to thrombophilia (surgery, 4 To whom correspondence should be addressed long immobilization, pregnancy, use of oral contraceptives, The aim of this study was to investigate the relationship antiphospholipid syndrome, and obesity). Only recently was it between recurrent miscarriages and factor V Leiden, discovered that the most common inherited defect is the prothrombin G20210A and C677T methylenetetrahydroresistance to activated protein C (aPCr), which is related, mainly, folate reductase (MTHFR) mutations. In this case-control to the factor V Leiden mutation (Dahlback et al., 1993; Bertina study the prevalence of factor V Leiden, prothrombin et al., 1994). This defect is quite common in Caucasians (3-7%) G20210A and C677T methylenetetrahydrofolate reductase (Rees et al., 1995; Lambropoulos et al., 1997) and is responsible mutations was determined in a consecutive series of 80 for 20-25% of all the cases of isolated thrombotic events and recurrent miscarriage patients and 100 controls. Fifteen of for 40-45% of all the cases of familial thrombophilia. More 80 recurrent miscarriage patients and four out of 100 recently, Poort et al. described a new polymorphism in the 3Ј controls carried the factor V Leiden mutation (19 versus untranslated region of the gene of prothrombin, the G20210A 4%, P ⍧ 0.003, odds ratio 5.5, 95% confidence interval polymorphism (Poort et al., 1996) . This polymorphism is (CI): 1.7-17). Seven of 80 recurrent miscarriage patients believed to be related to high prothrombin levels in the plasma and two of 100 controls were carriers of the prothrombin of these patients. The G20210A polymorphism is quite common G20210A mutation (9 versus 2%, P ⍧ 0.038, odds ratio in the normal population (0.7-4.0%) (Rosendaal et al., 1998), 4.6, 95% CI: 0.9-23.2). Six of 80 recurrent miscarriage while it is responsible for 6.2% (Poort et al., 1996) of all the women and 15 of 100 controls were homozygotes for the cases of thromboses. On the other hand, homozygosity for the C677T MTHFR mutation (8 versus 15%, P ⍧ 0.134, odds mutation C677T in the gene encoding methylenetetrahydrofolate ratio: 0.4, 95% CI: 0.1-1.2). Our results suggest that the reductase (MTHFR) results in decreased synthesis of 5-methylpresence of factor V Leiden and prothrombin G20210A tetrahydrofolate, the primary methyl donor in the conversion of polymorphism, but not MTHFR C677T homozygosity, homocysteine to methionine, and the resulting increase in plasma could be additional risk factors for recurrent miscarriages.
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homocysteine concentrations is a risk factor for venous and Furthermore, it was suggested that the prevalence of factor arterial thromboses (Frosst et al., 1995; de Franchis et al., 1996 ; V Leiden and prothrombin G20210A mutations is more Arruda et al., 1997; Margaglione et al., 1998) . prominent in second trimester, primary fetal losses and it Data accumulated over the past years suggest a possible is independent of the existence of additional pathology association between thrombophilia and fetal loss (Brenner predisposing to recurrent fetal losses.
and Blumenfeld, 1997). A clear association has been Key words: factor V Leiden/miscarriage/MTHFR C677T mutaestablished between fetal loss and certain thrombophilic tion/prothrombin G20210A mutation states, such as antiphospholipid syndrome (APS), antithrombin (AT) deficiency and combined defects (Sanson et al., 1996; Regan, 1998) . While several reports have suggested an increase in the Introduction prevalence of aPCr (Rai et al., 1996; Brenner et al., 1997) and factor V Leiden (Grandone et al., 1997; Ridker et al. , Recurrent fetal loss is a frequent health problem, with three or more affecting 1-2% and two or more affecting up to 5% 1998; Brenner et al., 1999) , not all reports concerning fetal loss and factor V Leiden mutation include data supporting this of women in the reproductive age (Regan, 1998) .
Although there is no consensus on the investigation of this association (Preston et al., 1996; Balasch et al., 1997; DizonTownson et al., 1997; Kutteh et al., 1998; Pauer et al., 1998) . condition, it is reasonable to offer a basic evaluation of couples with recurrent pregnancy losses. The tests to be considered These uncertainties about the exact role of factor V Leiden in fetal loss may have resulted from bias concerning the selection are: (i) endocrine evaluation; (ii) hysterosalpingography (HSG); (iii) parental karyotypes; (iv) endometrial biopsy and (v) of the patients regarding their prior evaluation of other known and the MTHFR C677T homozygosity between recurrent miscarriage causes of fetal loss, the number of previous miscarriages, and patients and controls. The odds ratio was used as a measure of the the type of miscarriage (first or second trimester, primary or strength of the association. All P values were two tailed, and 95% secondary).
CI were calculated.
Moreover, there are a few reports (Kutteh et al., 1998; Brenner et al., 1999) evaluating the role of prothrombin G20210A mutation and MTHFR C677T polymorphisms and Results recurrent fetal losses. The aim of this case-control study was to investigate the relationship between recurrent miscarriages Concerning the factor V Leiden mutation, 15 out of 80 recurrent miscarriage patients and four out of 100 controls and factor V Leiden, prothrombin G20210A and C677T methylenetetrahydrofolate reductase mutations.
carried the factor V Leiden mutation (19 versus 4%, P ϭ 0.003, odds ratio 5.5, 95% CI: 1.7-17). No factor V Leiden homozygote was found in the whole setting.
Materials and methods
Concerning the prothrombin G20210A polymorphism, seven
In this case-control study the prevalence of factor V Leiden, prothromout of 80 recurrent miscarriage patients and two out of 100 bin G20210A and C677T methylenetetrahydrofolate reductase controls were carriers of the prothrombin G20210A mutation mutations was determined in a consecutive series of 80 women (9 versus 2%, P ϭ 0.038, odds ratio 4.7, 95% CI: 0.9-23). Of the 15 women who were carriers of the factor V nine had uterine septum, six had polycystic ovary syndrome (PCO), Leiden mutation six had additional pathologies, which could five had uterine fibroids. None of the patients had a history of potentially predispose them to recurrent miscarriage (two had thrombo-embolic event.
fibroids, one had intrauterine septum, one had autoantibodies
The control group consisted of 100 age-matched women (age range and two had PCO). Of the seven women who were carriers of 30-45 years, mean 35) of the same ethnic origin. They were medical the prothrombin G20210A polymorphism one had fibroids and personnel or were hospitalized in the gynaecology department for PCO and one had intrauterine septum. The comparison of causes not pertaining to miscarriages. They had no personal or family women without additional pathology and controls is shown in history of thrombosis. All the subjects gave informed consent for the study.
Interestingly, there is no statistical difference in the Methods prevalence of factor V Leiden and prothrombin G20210A DNA was extracted from whole blood as per standard protocols.
mutations between women who have additional pathology and those who have not.
Factor V Leiden mutation
In order to investigate whether women with three or more
We performed a hot start polymerase chain reaction (PCR) using the miscarriages more frequently carry the factor V Leiden and primers FV1 and FV2 as previously described. The PCR product was prothrombin G20210A mutations than women with only two digested by the restriction enzyme Mnl 1 (Beauchamp et al., 1994) .
miscarriages, the prevalence of these two mutations is comProthrombin G20210A polymorphism pared between the two groups of patients. Three out of 35 women with two recurrent fetal losses (8.5%) and 12 out of
We performed a hot start PCR using the primers PT1 and PT2 followed by digestion of the product with the restriction enzyme 45 with three or more (26.6%) carried the factor V Leiden
Hind III (Makris et al., 1997) .
mutation (P ϭ 0.04). Two out of 35 women with two recurrent fetal losses (5.7%) and four out of 45 with three or more (8.8%)
Methylenetetrahydrofolate reductase C677T homozygosity carried the prothrombin G20210A polymorphism (P ϭ 0.39).
Amplification of a 198bp DNA fragment was performed, followed
From the 61 women with first trimester abortions, nine
by Hinf I digestion, as described elsewhere (Kluijtmans et al., 1998) .
(14.7%) were carrying the factor V Leiden and five (8.1%) the prothrombin mutation. From the 19 women with second
Statistical analysis
trimester abortions six (31.5%) were carrying the factor V The χ 2 statistic was used to test the significance of any difference in the prevalence of factor V Leiden, the prothrombin G20210A mutation
Leiden and two (10.5%) the prothrombin mutation (Table II) . (n ϭ 100) (95% CI) miscarriages (n ϭ 100) 95% CI) (n ϭ 55) (n ϭ 25) FVL mutation n (%) 14 (25.4) 4 (4) 8.2 (2.5-26)) Ͻ0.001 1 (4) 4 (4) 1.0 (0.1-9.3) 1.0 II G20210A mutation n (%) 6 (10.9) 2 (2) 6 (1.1-30) 0.02 1 (4) 2 (2) 2.0 (0.1-23) 0.5 Either mutation n (%) 20 (36.3) 6 (6) 8.9 (3.3-24) Ͻ0.001 2 (8) 6 (6) 1.3 (0.2-7.1) 0.7
These results suggest that the prevalence of factor V Leiden demonstrated a 4-fold, 2.2-fold and 4-fold increase correspondingly in the prevalence of factor V Leiden in women with fetal is more prominent in second trimester fetal loss, while the loss compared to controls. The case patients were unselected in prevalence of prothrombin G20210A does not differ between the work of Grandone et al. and Ridker et al. and (Table III) . Both factor V On the other hand, there is a number of reports suggesting Leiden and prothrombin G20210A constitute a significant risk that factor V Leiden is not a predisposing factor for recurrent factor if primary recurrent miscarriages are considered.
fetal loss (Balasch et al., 1997; Dizon-Townson et al., 1997; Kutteh et al., 1998; Pauer et al., 1998) .
Discussion
Dizon-Townson et al. found that none of the 40 selected The present report documents a clear association between women with three or more recurrent fetal loses (22 of first factor V Leiden mutation and fetal loss (odds ratio ϭ 5.5).
and 18 of second-trimester) and none of the 25 female controls The prevalence of factor V Leiden mutation is more prominent carried the factor V Leiden mutation. In contrast, the mutation among women with primary, three or more, second trimester was present in one male partner for each group (Dizon-(although it is still statistically significant in first trimester) Townson et al., 1997) . Since the carrier status of the male abortions, while it does not differ between women with and partner does not affect the pregnancy outcome (Preston et al., without additional pathology. 1996) , the results are not relevant and larger numbers of cases Factor V Leiden is a common mutation in Caucasians (Rees and controls should be expected to be enrolled in the study. et al., 1995) , and the prevalence of 4% in the control group Pauer et al. compared the prevalence of factor V Leiden is similar with the 4.3% reported for the population of Greece between 84 unselected women with a history of two or more (Lambropoulos et al., 1997) .
fetal losses (64 of first and 20 of second trimester) and 87 Three recent case-control studies have documented an unselected controls and found that 10.7% of patients and 9.2% association between factor V Leiden and fetal loss (Grandone of controls were carriers of factor V Leiden, while the frequency of carriership was more prominent in the group of et al., 1997; Ridker et al., 1998; Brenner et al., 1999) and second trimester fetal losses (15 versus 9.4%) (Pauer et al., corrected by the use of folic acid during pregnancy, thus confounding the results. 1998). This study might have possible bias in the control population, i.e. they were a group of unselected persons who Taken together the data of the present report suggest that factor V Leiden and prothrombin G20210A can be found in could have suffered thrombosis, thus would be expected to have a higher prevalence of factor V Leiden.
approximately one out of four women with a history of fetal loss, whether they carry additional pathology or not. The Kutteh et al. studied 50 unselected women with three or more fetal losses of first (91.7%) and second trimester (8.3%).
prevalence is more prominent when it comes to second trimester (one out of 2.5 women), or primary fetal loss (one A total of 28 of them had primary and 22 secondary fetal losses. The control group consisted of 50 women without out of three women). Nevertheless, in order to evaluate the necessity of routinely screening recurrent miscarriage women history of thrombosis or miscarriage. There was no statistical difference in the prevalence of factor V Leiden between the for thrombophilic mutations and intervening therapeutically, large-scale prospective studies should be performed. two groups, i.e. 2 versus 4% (Kutteh et al., 1998) . The possible bias in this study could be in the case group, which consisted of women with mainly first trimester, secondary abortions, where the prevalence of the mutation seems to be much lower.
